In advanced NSCLC, the CAP/IASLC/AMP guidelines state that ALK genetic abnormalities can be IHC screened based on highly specific antibodies (D5F3 or 5A4 clones) on CB if cytological material is the only tumor sample available.15 This evidence concerns the gene ALK and non-small cell lung carcinoma.